Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
12 ter Quai Perrache
Bureaux Convergence, Bat. A
Ilot Saint-Joseph
Lyon69002
FRAT: +33 478766101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
674
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
stocks
Poor organic growth obscured by acquisition for ASX listed share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,866.40 | 36.70 | -0.41% |
| CAC 40 | 8,258.26 | 142.51 | 1.76% |
| DAX 40 | 25,389.10 | 500.54 | 2.01% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 64,848.46 | 309.73 | -0.48% |
| NZX 50 Index | 13,078.18 | 107.90 | 0.83% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,638.40 | 38.20 | -0.44% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |